The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...

CureVac ( ($CVAC) ) just unveiled an update. On January 6, 2026, CureVac N.V. completed a post-offer reorganization tied to BioNTech SE’s exchange ...

The biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors. It owns and manages an AI developer, InstaDeep. Showing their approval, those market ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...

Citing four unnamed people "familiar with the situation," this effort will be based on findings that were apparently filed with the federal government's Vaccine Adverse Event Reporting System. The ...

BioNTech (NASDAQ:BNTX) is preparing to release its quarterly earnings on Monday, 2025-11-03. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

BioNTech and Chinese peer Duality Biologics announced before market open that a phase 3 clinical trial of their cancer drug trastuzumab pamirtecan met its primary endpoint of progression-free survival ...

Pfizer and BioNTech previously announced that their jointly developed COVID-19 vaccine showed over 90% effectiveness in preventing infection based on initial trial data, although scientists ...